Bristol Myers Squibb (NYSE: BMY) has received accelerated FDA approval for Augtyro (repotrectinib), a treatment designed for patients 12 years and older with NTRK gene fusion-positive solid tumors. This approval, pivotal for patients with advanced stages of cancer where surgical options could cause severe morbidity, marks a significant advancement in targeted cancer therapy. Clinical Trial […]
Novartis has achieved a major milestone in the treatment of IgA nephropathy (IgAN), reporting a 38.3% reduction in proteinuria in a pivotal Phase III trial. The study, dubbed APPLAUSE-IgAN, tested Fabhalta (iptacopan), an investigational Factor B inhibitor, demonstrating not only effectiveness in reducing protein levels in urine—a key marker for kidney disease progression—but also a […]
In a significant development for patients with relapsed or refractory follicular lymphoma, BeiGene, Ltd. has announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BRUKINSA (zanubrutinib). This marks the treatment as the first and only BTK inhibitor approved for adult patients in the U.S. who have undergone two or more lines […]